Saturday, May 30, 2026

#WHO DG's #remarks at the press #briefing on the #Bundibugyo #Ebola #outbreak – 30 May 2026 (Edited)

 


    Minister of Health, Dr Kamba,

    Minister of Communications, Mr Katembwe,

    Governor of Ituri, Lieutenant General Nkashama,

    Dear partners, friends and WHO colleagues,

    Good afternoon Bunia,

    It is a privilege to be here in Bunia. I wish the circumstances were different, but I came because the people of Ituri, the Kivus, and all of DRC deserve to know they are not alone.

    We are not here to tell people what to do. We are here to listen. Communities understand their own challenges and their own solutions. Our role is to support you in implementing those solutions, together. Community ownership is what will bring this outbreak to an end.

    During my visit I hope to meet with women’s groups, religious leaders, business leaders, young people and others during my stay here today and tomorrow. Building trust takes time, and it starts with listening.

    Earlier today I met with the Ministers, the Governor, the Congolese Red Cross, community leaders, Africa CDC, UNICEF and WFP. Yesterday in Kinshasa, I met with Prime Minister Judith Suminwa Tuluka to discuss the outbreak and the government-led response.

    I appreciated her commitment to ensuring that investments made during this response help strengthen DRC’s health system over the long term, because what we build here should last well beyond this outbreak.

    I also met with the UN Country Team, health and humanitarian partners, and the diplomatic corps, and I am grateful for their continued support. We are here to work under the leadership of the Government of DRC, in service of its people.

    And that service goes beyond Ebola.

    While we fight this outbreak alongside you, we are committed to ensuring that other essential health services and humanitarian assistance continue to be provided to communities across Ituri and beyond.

    DRC has faced Ebola before, sixteen times, and has ended every outbreak. This is the seventeenth. That history gives me real confidence.

    This outbreak is caused by the Bundibugyo virus, for which no licensed vaccine or treatment currently exists.

    But this is not without hope.

    Ebola caused by the Bundibugyo virus can be survived with good medical care, and some people here in Ituri have already recovered. Seeking care early makes a real difference.

    WHO is also working with partners to advance safe and effective vaccines and treatments through clinical trials.

    Hand hygiene matters. Sharing accurate information matters. And safe, dignified burials matter too. I understand how painful it is to lose someone, and how much it means to honour them properly.

    But certain practices, including touching the bodies of those who have died from Ebola, can spread the virus further. While we grieve for those we have lost, we must do everything we can so that we do not lose another. Protecting each other, even in grief, is one of the hardest and most important things we can do.

    To those who have already contributed to the response, thank you. More support is still needed. I would also ask countries that have imposed travel bans or border closures to reconsider. These measures make the response harder, and they discourage the transparency that saves lives.

    WHO will remain alongside DRC for as long as it takes. Our commitment doesn’t end when an outbreak does. You are not alone in this. We are here, we are with you, and we will see this through together. We want to leave behind health workers, hospitals, laboratories and services that will serve the people of Ituri for many years to come.

    Merci beaucoup.

Source: 


Link: https://www.who.int/news-room/speeches/item/who-director-general-s-remarks-at-the-press-briefing-on-the-on-the-bundibugyo-ebola-outbreak---30-may-2026

____

#Risk #assessment #guidelines for diseases transmitted on aircraft (RADIGA) – #Ebola disease #update (ECDC, summary)

 


Background 

    The ongoing outbreak of Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo (DRC) and Uganda reported in May 2026 [1] has prompted ECDC to review its operational guidance relevant to air travel. 

    In this context, updated guidance is needed to support preparedness and public health action if a case is identified during or after a flight. 

    This ECDC rapid scientific advice builds on the Ebola disease content previously included in the haemorrhagic fevers chapter of the ‘Risk assessment guidelines for diseases transmitted on aircraft (RADIGA)’ [2]. 

    In the original 2010 guidance, Ebola disease was included under haemorrhagic fevers; in 2011, the guidance was expanded to cover additional diseases. 

    This updated information is intended to support public health authorities and other competent national authorities in European Union/European Economic Area countries by providing actions to consider after the identification of a suspected or confirmed Ebola disease case during or after a flight. 

    Early recognition of the disease and risk assessment are needed to support an appropriate public health response when a potentially infectious passenger is identified during or after a flight, while avoiding unnecessary alarm or disruption to air traffic. 


Methods 

    The methods used to develop the original operational guidance are described in the RAGIDA – Part 2 document [2]. 

    For this rapid scientific advice, the content relevant to Ebola disease was reviewed and adapted from the haemorrhagic fevers chapter of that guidance. 

    The text was updated, where needed, in light of evidence and operational experience accrued since the publication of the 2011 guidance. 

    To produce this update, ECDC experts reviewed the peer-reviewed and grey literature for reports relevant to Ebola disease and air travel (Annex 1) and consulted additional operational and guidance documents relevant to public health management in relation to air travel (Annex 2).  


Results of the literature review 

    The literature search did not identify any published reports describing orthoebolavirus transmission events associated with air travel

    After the 2013–2016 Ebola disease outbreak in West Africa, several publications described travellers who took commercial flights from West Africa to such countries as the United Kingdom, the United States (US) and Italy who were subsequently diagnosed with Ebola disease [3-7]. 

    However, these reports did not describe symptoms occurring during the flight. 

    In one of these publications, an imported case was detected after the passenger arrived in the US. 

    Public health authorities carried out contact tracing of passengers and crew members who had been on the same flight, as the date of symptom onset was unclear. None of the traced contacts were later found to be positive for Ebola virus infection [5]. 


Ebola disease case definitions 

    For the purposes of this guidance, an index case is a person under investigation or a confirmed case identified during or after a flight, based on the applicable outbreak-specific case definitions in use at the time. 

    For the current outbreak of Ebola disease caused by Bundibugyo virus in DRC and Uganda, the relevant case definitions are available on the ECDC website [8].  

    In relation to air travel, the key considerations that might prompt contact tracing or other public health action are whether the person met the applicable case definition and was symptomatic during the flight. 


Detection of an index case 

    In this guidance, an ‘index case’ is a person under investigation or a confirmed case identified in relation to a flight. 

    The distinction between identification during a flight or after a flight reflects when the case first comes to the attention of the crew or public health authorities. 

    In both situations, the key question is whether or not the person was symptomatic during the flight, because Ebola disease is not considered transmissible before symptom onset. 

    Symptoms compatible with Ebola disease may include fever, severe headache, muscle pain, weakness, fatigue, sore throat, vomiting, diarrhoea, abdominal pain, or unexplained bleeding or bruising. 

 (...)

Suggested citation: European Centre for Disease Prevention and Control. Rapid Scientific Advice. Risk assessment guidelines for diseases transmitted on aircraft (RADIGA) – Ebola disease update. ECDC: Stockholm; 2026.   

© European Centre for Disease Prevention and Control, Stockholm, 2026 

Source: 


Link: https://www.ecdc.europa.eu/en/publications-data/risk-assessment-guidelines-diseases-transmitted-aircraft-radiga-ebola-disease

____

History of Mass Transportation: The Romanian Railways Class 95 Diesel Mechanical Shunter


 {Click on Image to Enlarge}


Source: 


____

#Outbreak at #Sea: The MV Hondius #Hantavirus #Cluster as a Sentinel for Global #Pandemic Readiness

 


{Summary}

The South Atlantic promises crystalline isolation. But the Dutch-flagged MV Hondius—an expedition vessel carrying 147 passengers and crew from 23 nations—harbored something else entirely between the Southern Cone and Antarctica [1, 2]. An invisible passenger. Epidemiologists trace this outbreak directly to dry land, theorizing the index case inhaled aerosolized rodent excreta during a Southern Cone bird-watching excursion [1].

(...)

Source: 


____

Sex differences in #vaccine-induced #neuraminidase cross-recognition and #protection against #H5N1 in mice

 


Abstract

Despite concerns about the spread and pandemic potential of H5N1, there is no commercial H5N1 vaccine. Seasonal influenza vaccines offer some cross-protection against H5N1, but to date there has been no consideration of whether protection differs between the sexes. We investigated immune responses and protection in adult male and female C57BL/6 mice following vaccination with either inactivated H1N1 or H5N1 (LAIV backbone) virus vaccines. Vaccination induced strong homologous antibody responses, with females generating greater total IgG than males against both H1N1 and H5N1 vaccine, which was primarily mediated by greater IgG responses to neuraminidase (NA) than hemagglutinin (HA) protein. IgG cross-recognition of H1N1 also was greater among H5N1 vaccinated females and was primarily caused by greater IgG responses to N1. IgG2b and IgG2c were the primary isotypes generated in response to these vaccines, with females having greater IgG2b responses and greater binding to FcγRIV for avian and human NA than males in response to both homologous and heterologous vaccination. Antibody-dependent complement deposition was measured as an FcR-mediated non-neutralizing response against HA and NA and was robust in both sexes. Vaccinated females had greater neutralizing antibody titers than males against the homologous vaccine virus, with limited cross-neutralizing antibodies detected in either sexes. Neuraminidase inhibition titers were greater in vaccinated females than males against the heterologous virus following H1N1 vaccination and against both the vaccine and heterologous viruses following H5N1 vaccination. When H1N1 and H5N1 vaccinated mice were challenged with a lethal dose of A/Texas/37/2024 H5N1, all H5N1 vaccinated mice were protected, regardless of sex. Among H1N1 vaccinated mice, while both sexes were protected against disease, H1N1 vaccinated females cleared virus faster than their male counterparts. These findings highlight that female-biased NA-specific antibodies result in greater cross-protection and should be considered in studies of influenza vaccines.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

NIH/NIAID Johns Hopkins Center of Excellence for Influenza Research and Response, 75N93021C00045

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.05.26.728011v1

____

#Coronavirus Disease Research #References (AMEDEO, May 30 '26)

 


    Antiviral Res

  1. MALOCCU S, Otsuka Y, Molchan E, Foti M, et al
    Identification of Nsp15 inhibitors restoring interferon-dependent antiviral activity against SARS-CoV-2.
    Antiviral Res. 2026;251:106443.
    PubMed         Abstract available


    BMJ

  2. YAMEY G
    Trump and RFK Jr have a new approach to global health: holding vulnerable people to ransom.
    BMJ. 2026;393:e387444.
    PubMed        


    Graefes Arch Clin Exp Ophthalmol

  3. XU X, Yu P, Wu S, Wang L, et al
    Repeatability of corneal diameter measured by Sirius versus IOLMaster 700 in myopic eyes: combined with consistency and relationship of sulcus-to-sulcus.
    Graefes Arch Clin Exp Ophthalmol. 2026 May 23. doi: 10.1007/s00417-026-07281.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  4. GIBAS KM, Head T, Broadley M, Mermel LA, et al
    Healthcare personnel masking: current practices and gaps in standardized thresholds.
    Infect Control Hosp Epidemiol. 2026 May 26:1-8. doi: 10.1017/ice.2026.10469.
    PubMed         Abstract available


    Int J Infect Dis

  5. BRUNVOLL SH, Fagerland MW, Nygaard AB, Ellingjord-Dale M, et al
    Long COVID symptoms before and 3-35 Months after SARS-CoV-2 infection in a Norwegian prospective cohort study, symptoms over the pandemic and different virus variants.
    Int J Infect Dis. 2026 May 27:108822. doi: 10.1016/j.ijid.2026.108822.
    PubMed         Abstract available


    J Infect

  6. LU L, Long Z, Chen F, Li Z, et al
    Global Disability-Adjusted Life Years Burden of Lower Respiratory Infections Caused by Streptococcus pneumoniae, Staphylococcus aureus, and Klebsiella pneumoniae, 1990-2021: A Systematic Analysis of the Global Burden of Disease Study 2021.
    J Infect. 2026 May 25:106768. doi: 10.1016/j.jinf.2026.106768.
    PubMed         Abstract available

  7. CORRAO G, Sguazzini E, Gori A, Monti E, et al
    All-cause mortality within seven days of COVID-19 vaccination: A matched cohort and self-controlled case series study in Lombardy, Italy.
    J Infect. 2026;93:106769.
    PubMed         Abstract available


    J Med Virol


  8. Correction to "Deep Sequencing Reveals Dual Evolution of SARS-CoV-2: Insights Into Defective Genomes From Wuhan-Hu-1 Variants to Omicron Subvariants".
    J Med Virol. 2026;98:e70987.
    PubMed        

  9. REPUSIC D, Korolija M, Livun A, Svagusa T, et al
    Multi-Layered Genomic and Clinical Analysis Identifies Novel Variants, Co-Occurring Single Nucleotide Polymorphism Pairs, and Clinical Determinants of Host-Pathogen Interaction in COVID-19 Severity.
    J Med Virol. 2026;98:e70984.
    PubMed         Abstract available


    Lancet

  10. GIOVANNONI G, Airas L, Bove R, Cutter GR, et al
    Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.
    Lancet. 2026;407:2195-2207.
    PubMed         Abstract available


    N Engl J Med

  11. ZIMMERMANN WH, Ensminger S, Kutschka I, Paitazoglou C, et al
    Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure.
    N Engl J Med. 2026;394:1991-2001.
    PubMed         Abstract available


    Nature

  12. SUZUKI R, Yamasoba D, Kimura I, Wang L, et al
    Author Correction: Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.
    Nature. 2026 May 29. doi: 10.1038/s41586-026-10665.
    PubMed        

  13. ZENG AGX, Nagree MS, Jakobsen NA, Shah S, et al
    Human haematopoietic stem cells remember inflammatory stress.
    Nature. 2026 May 27. doi: 10.1038/s41586-026-10522.
    PubMed         Abstract available


    Radiology

  14. SPOSATO A, Mazzola MA, Kunst MM
    Case 346: gamma-Aminobutyric Acid A Receptor Encephalitis.
    Radiology. 2026;319:e251976.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, May 30 '26)

 


    Cell

  1. DE SA KSG, Silva J, Bayarri-Olmos R, Baker CA, et al
    A causal link between autoantibodies and neurological symptoms in long COVID.
    Cell. 2026;189:3214-3235.
    PubMed         Abstract available

  2. WALL EC, Richter AG
    Autoantibodies in long COVID: A mechanistic foothold in a heterogeneous disease.
    Cell. 2026;189:3179-3180.
    PubMed         Abstract available

  3. FOURNIER M, Vanderkerken M, Dorgham K, Bastard P, et al
    Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections.
    Cell. 2026;189:3236-3253.
    PubMed         Abstract available


    Epidemiol Infect

  4. KITAMURA N, Kondo N, Ith S, Okuyama M, et al
    Post-pandemic immunity debt for paediatric infectious diseases in Japan between 2014 and 2024.
    Epidemiol Infect. 2026;154:e67.
    PubMed         Abstract available


    J Immunol

  5. WANG Q, McManus LR, Levine KS, Blanc R, et al
    A multiplexed, systems-based approach for prediction of antibody neutralization breadth for soluble human receptors.
    J Immunol. 2026;215:vkag106.
    PubMed         Abstract available


    J Infect

  6. WEE LE, Ho RWL, Lim JT, Lim SK, et al
    Real-world effectiveness of influenza vaccination amongst children aged under 5 in a tropical setting.
    J Infect. 2026 May 26:106771. doi: 10.1016/j.jinf.2026.106771.
    PubMed         Abstract available

  7. MUNRO AP, Ferrari M, Kinsley R, Egan D, et al
    A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine.
    J Infect. 2026 May 18:106759. doi: 10.1016/j.jinf.2026.106759.
    PubMed         Abstract available

  8. KIM HK, Jo S, Min KD, Cho SI, et al
    Effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 reinfection in Patients With Cancer: Evidence From a Nationwide Target Trial Emulation.
    J Infect. 2026 Apr 28:106753. doi: 10.1016/j.jinf.2026.106753.
    PubMed         Abstract available


    J Virol

  9. LOES AN, Tarabi RAL, Li SH, Atkinson RK, et al
    Strain-specific differences in the response to egg-derived versus recombinant protein influenza vaccines.
    J Virol. 2026 May 27:e0031726. doi: 10.1128/jvi.00317.
    PubMed         Abstract available


    J Virol Methods

  10. ZENG Q, Liu L, Wang T, Zhang C, et al
    Artificial intelligence-assisted technology to reduce turnaround time for rapid diagnosis of infectious diseases.
    J Virol Methods. 2026;344:115392.
    PubMed         Abstract available


    PLoS Biol

  11. ZHOU F, Periasamy S, Jackson ND, Cheng WS, et al
    Redundant and distinct mechanisms suppress innate immune activation during SARS-CoV-2 infection.
    PLoS Biol. 2026;24:e3003808.
    PubMed         Abstract available


    PLoS Med

  12. JANSEN E, Bockstal V, Herschke F, Olsson Gisleskog P, et al
    Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials.
    PLoS Med. 2026;23:e1004609.
    PubMed         Abstract available


    PLoS One

  13. SILVA-VALENCIA J, Tu K, Moineddin R, Butt DA, et al
    Trends in pulmonary exercise testing utilization after the COVID-19 pandemic in Ontario: A population-cohort study.
    PLoS One. 2026;21:e0349020.
    PubMed         Abstract available

  14. WARNE DJ, Varghese A, Brewster A, Browning AP, et al
    Bayesian uncertainty quantification to identify population level vaccine hesitancy behaviours.
    PLoS One. 2026;21:e0349499.
    PubMed         Abstract available

  15. AKIN HY, Tuncali T, Gencer EB, Cengiz Seval G, et al
    Innate immunogenetic synergy between KIR and Neanderthal-derived OAS variants predicts COVID-19 outcomes.
    PLoS One. 2026;21:e0345137.
    PubMed         Abstract available

  16. SIROTIAK Z, Oberhauser AM, Sirotiak AM, Nettleton KA, et al
    Exploring the perceived impact of physical activity on physical and mental health among individuals with long COVID: A qualitative interview inquiry.
    PLoS One. 2026;21:e0350121.
    PubMed         Abstract available

  17. FIORE E, Taio G, Morandi N, Mazzotta E, et al
    Lung ultrasonography to assess efficacy of intranasal and parenteral vaccinations for bovine respiratory disease (BRD) in dairy calves.
    PLoS One. 2026;21:e0349953.
    PubMed         Abstract available

  18. AGYEI G, El-Duah P, Dumevi RM, Muzeniek T, et al
    Serological responses to SARS-CoV-2 in urban and rural Ghana: Antibody waning and implications for long-term population immunity.
    PLoS One. 2026;21:e0348281.
    PubMed         Abstract available

  19. ROSSI SL, Cheng DM, Sereda Y, Truong V, et al
    COVID-19 pandemic-related stress and substance use behaviors among people with HIV - a mixed method analysis.
    PLoS One. 2026;21:e0349567.
    PubMed         Abstract available

  20. YEO HY, Park JY, Marsh S, Castelino L, et al
    Evidence mapping of preference elicitation for non-pharmaceutical interventions targeting respiratory viral transmission: A scoping review protocol.
    PLoS One. 2026;21:e0344828.
    PubMed         Abstract available

  21. KUBILIUTE I, Zaboras E, Majauskaite F, Urboniene J, et al
    Predicting severe COVID-19 disease in adults: A single-centre cohort study during the first three pandemic waves in 2020-2021 in Vilnius, Lithuania.
    PLoS One. 2026;21:e0350112.
    PubMed         Abstract available

  22. BRIDGMAN WH, Safta C, Ray J
    A scalable variational method for estimating the latent infection-rate field of an outbreak.
    PLoS One. 2026;21:e0350090.
    PubMed         Abstract available

  23. STOTZER E, Graner S, Sengpiel V, Wessberg A, et al
    Crisis leadership and strategic decisions in Swedish maternity care during the COVID-19 pandemic: A deductive analysis from the COPE staff project.
    PLoS One. 2026;21:e0346625.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  24. ADIGA A, Chopra A, Wilson ML, Ravi SS, et al
    A high-resolution, US-scale digital similar of interacting livestock, wild birds, and human ecosystems for multihost epidemic spread.
    Proc Natl Acad Sci U S A. 2026;123:e2507074123.
    PubMed         Abstract available


    Vaccine

  25. JUFUKU R, Shinchi H, Murata K, Chan M, et al
    TLR7 ligand-cyclodextrin conjugate is a promising adjuvant for intranasal influenza vaccine.
    Vaccine. 2026;86:128762.
    PubMed         Abstract available

  26. LIU R, Fan Y, Xiong S, Lin J, et al
    Drivers of and implementation strategies for influenza vaccination for cardiovascular populations in China: a scoping review.
    Vaccine. 2026;86:128761.
    PubMed         Abstract available

  27. OKUBO Y, Honjyo R, Uda K, Miyairi I, et al
    Nationwide survey for household preparedness and vaccination acceptance during a novel influenza pandemic scenario in Japan, 2025.
    Vaccine. 2026;86:128738.
    PubMed         Abstract available

  28. MYBURGH L, van Loon K, Koetsier J, Hansen Q, et al
    Conjugate vaccine technology enhances responses to influenza virus.
    Vaccine. 2026;86:128728.
    PubMed         Abstract available

  29. HALFMANN PJ, Duffy A, Wang T, Kawaoka Y, et al
    Evaluating the immunogenicity of clade 2 and clade 3 sarbecovirus spike protein nanoparticle vaccines in Syrian hamsters.
    Vaccine. 2026;84:128653.
    PubMed         Abstract available

  30. LAMBERT D, Luisi N
    Prevalence and correlates of COVID-19 vaccine uptake among sexual and gender minority adolescents in the southern United States.
    Vaccine. 2026;84:128661.
    PubMed         Abstract available

  31. SHEN Y, Shahn Z, Robertson MM, Gebo K, et al
    Effect of a third COVID-19 vaccine dose on the incidence of Long COVID among adults who completed a primary vaccine series: a target trial emulation in a community-based cohort.
    Vaccine. 2026;84:128666.
    PubMed         Abstract available

  32. MULLER MP, Soe P, Shulha HP, Isenor JE, et al
    mRNA COVID-19 vaccine safety in adults from the Canadian national vaccine safety network.
    Vaccine. 2026;84:128630.
    PubMed         Abstract available

  33. AMOAKO N, Cohuet S, Adjei MR, Gurry C, et al
    COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2 in Ghana, June 2022 to March 2024.
    Vaccine. 2026 Feb 17:128310. doi: 10.1016/j.vaccine.2026.128310.
    PubMed         Abstract available

  34. BALAM S, Kane F, Traore B, Konate D, et al
    Kinetics and seroprevalence of anti-SARS-CoV-2 antibodies in vaccinated and unvaccinated health workers in Bamako, Mali, November 2021-February 2023.
    Vaccine. 2025 Sep 1:127680. doi: 10.1016/j.vaccine.2025.127680.
    PubMed         Abstract available

  35. GREY-JOHNSON M, Muhammad AK, Sillah F, Jones CJ, et al
    COVID-19 testing acceptance among symptomatic individuals screened for a randomized clinical trial in The Gambia.
    Vaccine. 2026;77 Suppl 1:127608.
    PubMed         Abstract available

  36. ANYANGO RO, Nyawanda BO, Onyando BO, Haidara FC, et al
    Factors associated with laboratory-confirmed SARS-Cov-2 infection among patients with severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 May 12:127234. doi: 10.1016/j.vaccine.2025.127234.
    PubMed         Abstract available

  37. GURRY CE, Mwenda JM, Nardone A, Cohuet S, et al
    Establishing the African region monitoring vaccine effectiveness (AFRO-MoVE) network for respiratory pathogens.
    Vaccine. 2024 Dec 31:126616. doi: 10.1016/j.vaccine.2024.126616.
    PubMed         Abstract available

  38. ONYANDO BO, Nyawanda BO, Onguru D, Haidara FC, et al
    Factors associated with mortality among patients aged 12 years and above requiring hospitalization for severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 Mar 1:126910. doi: 10.1016/j.vaccine.2025.126910.
    PubMed         Abstract available

  39. KUSEMERERWA S, Ankunda V, Ongaria TA, Abaasa A, et al
    COVID-19 vaccination status and associated factors among patients presenting with COVID-19-like symptoms in Uganda.
    Vaccine. 2025 Mar 6:126984. doi: 10.1016/j.vaccine.2025.126984.
    PubMed         Abstract available

  40. ABAASA AM, Kusemererwa S, Ankunda V, Ongaria TA, et al
    Effectiveness of COVID-19 vaccine against SARS-CoV-2 infection among symptomatic COVID-19 patients in Uganda.
    Vaccine. 2025 Mar 6:126976. doi: 10.1016/j.vaccine.2025.126976.
    PubMed         Abstract available

  41. SIKUVI K, Nghitukwa N, Kakehongo N, Katjitae I, et al
    Effectiveness of COVID-19 vaccines against laboratory-confirmed SARS-CoV-2 infection amongst health workers, Windhoek, Namibia.
    Vaccine. 2025 Mar 11:126977. doi: 10.1016/j.vaccine.2025.126977.
    PubMed         Abstract available

  42. CRAWLEY AW, Murphy K, Plumb ID, Ocansey GA, et al
    Challenges and enablers to establishing COVID-19 vaccine effectiveness studies in the World Health Organization Africa region: A mixed-methods evaluation of the African region monitoring vaccine effectiveness (AFRO-MoVE) network.
    Vaccine. 2025 Mar 20:126823. doi: 10.1016/j.vaccine.2025.126823.
    PubMed         Abstract available

  43. JOHNSTONE SL, Shapiro D, Chiwandire N, Matoti L, et al
    Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related hospitalisation amongst adult members of a private health insurance plan in South Africa during the Delta and Omicron periods: A test-negative case-control study.
    Vaccine. 2025 Apr 2:127068. doi: 10.1016/j.vaccine.2025.127068.
    PubMed         Abstract available


    Virology

  44. UNO N, Ross TM
    Intramuscular administration of influenza hemagglutinin in one hind leg elicits similar protective immune responses as administration in two hind legs.
    Virology. 2026;621:110961.
    PubMed         Abstract available


    Virus Res

  45. FARSIU N, Mahani FK, Arefinia N, Charostad J, et al
    From Legacy to Innovation: A Comprehensive Review of Vaccine Platforms Against Viral Infections.
    Virus Res. 2026 Apr 16:199730. doi: 10.1016/j.virusres.2026.199730.
    PubMed         Abstract available

  46. VAN DIJK LLA, Rijsbergen LC, Havelaar AC, den Hartog Y, et al
    Innate airway responses shape permissiveness to human respiratory syncytial virus.
    Virus Res. 2026;368:199734.
    PubMed         Abstract available

  47. JANGJOU A, Izadpanah P, Moqhadas M, Faramarzi H, et al
    QT interval prolongation and its related factors before and after receiving lopinavir-ritonavir in the COVID-19 era: a historical cohort study.
    Virus Res. 2026;368:199739.
    PubMed         Abstract available

Friday, May 29, 2026

#Ebola disease caused by #Bundibugyo virus, #DRC & #Uganda (WHO D.O.N., May 29 '26)

 


Situation at a glance

    The Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo and Uganda continues to evolve rapidly, with increasing case numbers, geographic spread, and ongoing cross-border transmission

    As of 27 May, a total of 906 suspected cases and 223 deaths among suspected cases have been reported in the Democratic Republic of the Congo

    As of 29 May, a total of 134 confirmed cases, including nine in Uganda, with 18 deaths among the confirmed cases, have been reported across both countries. 

    This is an additional 49 confirmed cases, eight confirmed deaths, 160 suspected cases and 47 suspected deaths since the last update on 21 May. 

    In addition, there is one confirmed case, an individual from the United States of America, who had treated patients in the Democratic Republic of the Congo and is currently receiving care in Germany

    In the Democratic Republic of the Congo, transmission is concentrated in Ituri, as well as North Kivu and South Kivu provinces, with challenges in contact tracing and follow-up, insecurity, inadequate isolation, care, and referral systems for patients complicating response efforts. 

    National authorities, in collaboration with WHO and partners, are implementing response measures including deployment of rapid response teams, delivery of medical supplies, strengthened surveillance, laboratory confirmation, infection prevention and control, the set-up of safe and optimized treatment centers, and community engagement.


Description of the situation

    Since the last Disease Outbreak News was published on 21 May 2026, the number of suspected and confirmed cases has increased rapidly in the Democratic Republic of the Congo. 

    In total, 906 suspected cases, including 223 deaths among suspected cases have been reported from Democratic Republic of the Congo; and 134 confirmed cases (nine in Uganda), including 18 deaths (one in Uganda) (CFR 14%) have been reported from the two countries as of 29 May. 

    Additionally, a medical doctor from the United States of America who was exposed as part of their work caring for patients in the Democratic Republic of the Congo tested positive on 17 May and was transported to Germany for treatment and care.

(...)


Democratic Republic of the Congo

    Since the last update dated 21 May, an additional 42 confirmed cases including eight deaths and 160 suspected cases including 47 deaths have been reported from the Democratic Republic of the Congo. 

    As of 27 May 2026, a total of 125 confirmed cases including 17 deaths (CFR 14%); and 906 suspected cases including 223 deaths have been reported from 13 health zones (HZ) in Ituri (7/36 HZ), North Kivu (5/35 HZ) and South Kivu Provinces (1/34 HZ) [1]. 

    Sixteen confirmed cases have been reported among health and care workers to date. 

    Epidemiological and laboratory investigations are ongoing to reclassify all suspected cases and deaths reported in the Democratic Republic of the Congo.

    The outbreak remains concentrated in Ituri Province, which accounts for 88% (110) of confirmed cases

    The highest confirmed case numbers in Ituri Province are reported from Bunia (37 cases), Rwampara (33 cases), Mongbwalu (20 cases), and Nyankunde (10 cases) HZ. 

    Of the 17 deaths among confirmed cases in the Democratic Republic of the Congo, 10 were male (nine were over 15 years old and one under 15) and seven were female (five over 15 years old and two under 15).

    A total of 774 samples have been collected as of 27 May. Of these, 648 samples (84%) have been analyzed, with 125 testing positive, representing a test positivity rate (TPR) of 19.2%. This is likely an underestimation of the actual positivity rate as over 100 samples are still awaiting testing and have been sent to Kinshasa for further analysis.

    As of 27 May, 2635 contacts have been listed in Ituri and North Kivu provinces.

    Security incidents against health facilities, and community resistance, have recently emerged as major operational challenges in Ituri Province, with three recent incidents reported in Mongbwalu and Rwampara HZ. These create additional risks for undetected transmission, disrupt outbreak response efforts, and reinforce the need to strengthen community protection and engagement activities

(...)


Uganda

    Since the last update dated 21 May, an additional seven confirmed cases have been reported from Uganda

    As of 29 May 2026, a total of nine confirmed cases including one death have been reported in Kampala (n=8) and Wakiso (n=1), Uganda. 

    Recent cases include a Ugandan driver who transported the first reported case, a Congolese health worker with linkage to the index case, a Congolese woman who travelled to Uganda for medical care, and two Ugandan health workers linked to earlier confirmed case.

    As of 26 May, a total of 436 contacts linked to the cases have been identified and are under follow-up. These include close household contacts and hospital contacts where the cases were hospitalized.

    Exposure risks are associated with healthcare settings and cross-border movements.

(...)


Epidemiology

    Bundibugyo virus disease (BVD) is a severe and often fatal form of Ebola disease caused by the Bundibugyo virus, one of the Orthoebolavirus species. 

    It is a zoonotic disease, with fruit bats suspected to be the natural reservoir. 

    Human infection is thought to occur through close contact with the blood or secretions of infected wildlife, such as bats or non-human primates, and it subsequently spreads from person to person through direct contact with the blood, secretions, organs, or other bodily fluids of infected individuals or contaminated surfaces or items. 

    Transmission is particularly amplified in health-care settings when infection prevention and control (IPC) measures are inadequate, and during unsafe burial practices involving direct contact with the deceased.

    The incubation period for BVD ranges from 2 to 21 days, and individuals are not infectious until symptom onset

    Early symptoms such as fever, fatigue, muscle pain, headache, and sore throat, are non-specific, which complicates clinical diagnosis and can delay detection. These symptoms then progress to gastrointestinal symptoms, organ dysfunction, and in some cases haemorrhagic manifestations. Case fatality rates in the past two BVD outbreaks, reported in Uganda and in the Democratic Republic of the Congo in 2007 and 2012, have ranged from approximately 30% to 50%.

    Differentiating BVD from other endemic febrile illnesses such as malaria is challenging without laboratory confirmation using PCR or antigen/antibody-based assays. 

    Control relies on rapid case identification, isolation and care, contact tracing, safe burials, and strong community engagement, as no approved vaccines or specific treatments currently exist for BVD.


Public health response

    Health authorities in the Democratic Republic of the Congo and Uganda, in collaboration with WHO and partners, are implementing comprehensive public health measures. WHO Director-General, Dr Tedros Adhanom Ghebreyesus, traveled to the Democratic Republic of the Congo on 28 May to support the ongoing response.

(...)


WHO risk assessment

    On 22 May 2026, WHO assessed the risk of the outbreak of BVD to be very high at the national level in the Democratic Republic of the Congo, high at the regional level, and low at the global level

    The risk assessment will be continuously reassessed in the coming days based on available and shared information.

(...)


WHO advice

    On 19 May 2026, the Director-General of WHO convened the first meeting of the IHR Emergency Committee, which issued the temporary recommendations on 22 May 2026 to States Parties. These recommendations underscore the importance of coordinated outbreak control, enhanced cross‑border collaboration, and sustained surveillance and preparedness to prevent further regional spread and ensure an effective public health response

    WHO advises against any restriction of travel to, or trade with, the Democratic Republic of the Congo or Uganda based on the currently available information. 

    WHO continues to closely monitor and, where necessary, verify travel and trade measures in relation to this event.

(...)

___

[1] Data source: Centre des opĂ©rations d'urgences de sante publique (COUSP-DRC) available at : SitRep MVE N° 013/2026 – National Institute of Public Health


Citable reference: World Health Organization (29 May 2026). Disease Outbreak News; Bundibugyo Virus Disease, Democratic Republic of the Congo and Uganda. Available at https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON605

Source: 


Link: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON605

____

#Italy, #Ebola: #Doctor returning from #DRC tests negative {so far} (Min. Health, May 29 '26)

 


Press release number 35 | Press release date: May 29, 2026


    The Ministry of Health informs that last night the Italian doctor from Doctors Without Borders who had come into contact with patients who tested positive for Ebola returned from the Democratic Republic of Congo. 

    The doctor is a surgeon who is asymptomatic but who nevertheless authorized the test, which came back negative

    The test was performed at the Spallanzani Hospital in Rome, where the doctor is currently in quarantine

    The Ministry recalls that there is no Ebola alert in our country

    The Ministry has been actively involved in all preparedness and surveillance activities since the outbreak began and is continuing to monitor the evolution of the epidemiological situation in coordination with the local authorities and national and local health authorities.

Source: 


Link: https://www.salute.gov.it/new/it/comunicato-stampa/ebola-negativo-il-test-della-dottoressa-rientrata-dal-congo/

____

Meeting of the #SAGE on #Immunization, March 2026: conclusions and recommendations {#COVID19 vaccines safety portion} (WHO, May 29 '26)

 


(...)

COVID-19 

    SAGE reviewed the latest epidemiological data on COVID-19 during the Omicron era, including the disease burden and post-COVID conditions, across population groups. 

    Evidence on the status of vaccine use globally and the safety, effectiveness and cost–effectiveness of currently available vaccines was also reviewed. 

    The global burden of severe COVID-19 has declined compared with earlier phases during the pandemic, largely due to widespread population immunity through vaccination and prior infection

    Nevertheless, COVID-19 continues to cause morbidity and mortality, particularly among older adults, individuals with comorbidities and people who are immunocompromised

    In terms of post-COVID-19 conditions, persistent symptoms following acute infection have been documented in both adults and children, although estimates of prevalence vary considerably across studies owing to differences in case definitions and study methods. 

    Vaccination may contribute to reducing the risk of post-COVID-19 conditions, primarily through prevention of severe disease. 

    In terms of the burden of COVID-19 during pregnancy and infancy in the Omicron era, the risk of severe disease and adverse maternal and fetal outcomes was lower than during the pandemic. 

    However, people who are pregnant remain at higher risk of severe disease in the Omicron era compared with those of a similar age who are not pregnant. 

    Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy has been associated with an increased risk of adverse maternal outcomes (e.g. intensive care unit admission) and pregnancy outcomes (e.g. preterm birth). 

    Data on infants infected with SARS-CoV-2, which are mainly from a few high-income settings, indicate that infants aged under 6 months may experience higher hospitalization rates than older children, although the frequency of severe outcomes is low and varies within these settings. 

    The currently available mRNA and protein subunit COVID-19 vaccines have an acceptable safety profile across age groups and risk categories, based on 5 years of accumulated COVID-19 vaccine safety data from clinical trials, post-marketing pharmacovigilance systems, surveillance platforms, post-authorization studies and international regulatory reviews. 

    Serious adverse events remain rare relative to the number of doses administered globally (>13 billion); also, most reported adverse events are mild or moderate and transient, typically resolving within a few days. 

    A limited number of rare, platform-specific adverse events have been identified, including thrombosis with thrombocytopenia syndrome (TTS) associated with adenovirus vector vaccines that are no longer being manufactured, and myocarditis/pericarditis associated with mRNA and protein vaccines

    However, myocarditis and pericarditis associated with the currently available mRNA and protein vaccines remain uncommon, and have a milder course than post-COVID or conventional myocarditis; hence, the overall benefit–risk balance continues to favour vaccination, particularly among populations at increased risk of serious COVID-19 outcomes. 

    Safety following repeated doses, including revaccination with variant-adapted vaccines, remains reassuring, with no new safety signals identified.{24} 

    Real-world evidence consistently shows that the vaccines are effective in reducing COVID-19 associated severe disease and death. 

    Vaccines adapted to Omicron lineages continue to provide meaningful protection against severe outcomes. 

    Routine periodic COVID-19 vaccine doses help to sustain protection, despite the relatively rapid waning of protection against infection and limited protection against symptomatic disease beyond 6 months

    Updated evidence on COVID-19 vaccination during pregnancy from observational studies, pregnancy registries, and surveillance systems across multiple countries has not identified safety concerns

    Currently it shows no increased risk of adverse maternal or pregnancy-related outcomes, including miscarriage, stillbirth, preterm birth or adverse outcomes in infants born to people vaccinated during pregnancy. 

    Vaccination during pregnancy is safe and it provides protection to the pregnant individual, against COVID-19 associated adverse pregnancy outcomes, and to infants aged under 6 months through maternal antibody transfer. 

    Cost–effectiveness analyses of COVID-19 vaccination consistently show that programmes targeting populations at high risk of severe outcomes (e.g. older adults or individuals with underlying health conditions) are generally cost-effective or even cost saving across a range of epidemiological scenarios. 

    Broader vaccination strategies may be cost-effective in certain contexts, depending on disease burden, vaccine costs and programmatic factors. 

    Most studies originate from high-income countries, limiting their generalizability to other settings.

    SAGE recommended that countries should consider routine COVID-19 vaccination for those groups at highest risk of severe COVID-19 disease

    These include oldest adults;{25}  older adults{26} with significant comorbidities or severe obesity; residents in care and long-term care facilities; and individuals aged 6 months or over, who are moderately or severely immunocompromised. 

    For these groups – whether they are unvaccinated or were vaccinated more than 6 months earlier – SAGE recommended at least one dose per year, and preferably two doses administered 6 months apart, owing to the waning of protection against severe COVID-19 disease by 6 months after the last dose. 

    Cost–effectiveness and programmatic feasibility should be considered when determining the number of doses to be administered per year.  

    SAGE also recommended that countries may consider routine COVID-19 vaccination of additional groups based on local context, cost–effectiveness and programmatic feasibility. 

    These additional groups include the following

        Older adults without significant comorbidities or severe obesity; adults (not included in the older adult category), adolescents and children with significant comorbidities or severe obesity; and health workers and other care providers. These groups, whether unvaccinated or previously vaccinated more than 6 months earlier, may be vaccinated with at least one dose per year. 

        People who are pregnant, whether unvaccinated or previously vaccinated more than 6 months earlier. This group may be vaccinated with one COVID-19 vaccine dose during each pregnancy, at any stage, though ideally during the second trimester. The aim is to optimize protection against severe COVID-19 for the pregnant person, prevent adverse pregnancy outcomes and protect the infant during the first months of life. 

        Previously unvaccinated healthy children aged 6–23 months. This age group may be vaccinated if a significant burden is documented; revaccination is not routinely recommended. 

    Some of the research priorities recommended by SAGE were further assessment of the burden, societal impact and vaccine effectiveness against post-COVID-19 condition, using the WHO standardized definition;{27}  studies on cost–effectiveness of COVID-19 vaccination, particularly in low- and middle-income countries, and among groups such as health workers and children; and studies on the social and behavioural drivers of COVID-19 vaccine uptake, to address hesitancy and guide interventions to achieve high confidence and uptake. 

    SAGE recommendations will inform the development of a WHO vaccine position paper on COVID-19 vaccines; the position paper will replace the WHO SAGE interim guidance reflected in the COVID-19 vaccines roadmap.{28} 

(...)

___

{24}   World Health Organization (2026). Global Advisory Committee on Vaccine Safety (GACVS): COVID-19 vaccines – Subcommittee. Geneva: WHO; [cited 2026 Mar 10]. Available from: https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/covid-19-vaccines/subcommittee, accessed 30 April 2026).

{25} Age cut-off should be determined by countries – often it is 75 or 80 years. 

{26}  Age cut-off should be determined by countries – often it is 50 or 60 years 

{27} WHO standardized definition for adults: Post-COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. (https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1, accessed 30 April 2026);  WHO standardized definition for children and adolescents: Post-COVID-19 condition in children and adolescents occurs in individuals with a history of confirmed SARS-CoV-2 infection, with at least one persistent physical symptom lasting for at least 12 weeks after testing positive, that impacts everyday functioning and cannot be explained by another diagnosis. (https://www.who.int/publications/i/item/WHO-2019-nCoV-Post-COVID-19-condition-CA-Clinical-case-definition-2023-1, accessed 30 April 2026) 

{28} WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines (https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.1, accessed 30 April 2026)

(...)

Source: 


Link: https://www.who.int/publications/journals/weekly-epidemiological-record

____

#USA, #Wastewater Data for Avian #Influenza #H5 (CDC, May 29 '26)

 


{Excerpt}

(...)

Time Period: May 17, 2026 - May 23, 2026

-- A(H5) Detection7 site(s) (1.6%)

-- No Detection438 site(s) (98.4%)

-- No samples49 site(s)


{Click on Image to Enlarge}



(...)

Source: 


Link: https://www.cdc.gov/wastewater/emerging-viruses/h5.html?

____

#Italy, Canine #rabies case in Vittorio Veneto: epidemiological #investigations underway. All #dogs and #cats must be vaccinated (LHA, May 29 '26)

 


(No. 97/2026) 

    On Wednesday, May 27, a case of rabies was detected in a crossbreed dog owned by an Italian woman living in the municipality of Vittorio Veneto, in the San Giacomo di Veglia area.

    The case was reported by a veterinary clinic, where the animal had been brought due to the onset of nervous symptoms consistent with the disease. 

    During the medical history reconstruction conducted with the owner and her family, it emerged that the dog had been brought to Italy illegally several months earlier following a tourist trip to Morocco by a relative of the woman.

    Given the animal's extremely serious clinical condition and the potential health risk, the dog was euthanized and immediately transferred to the Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe) – National Reference Center for Rabies, which confirmed the diagnosis and the origin of the virus in Morocco. 

    Rabies is a viral disease spread through direct contact between animals and occasionally from infected animals to humans. 

    The consequences can be very serious, which is why it's important to promptly identify any potential contact with the dog in the previous two weeks. 

    Owners of dogs who may have come into contact with the rabid animal (photo of which is attached to this press release) are encouraged to contact the veterinary services of the Local Health Authority (ULSS).  

    The Public Health and Hygiene Service (SISP) and the Animal Health Service of Local Health Authority 2 have already conducted epidemiological investigations and traced the exposed people and dogs

    The people have been given post-exposure prophylaxis, an effective measure to prevent any risk of disease development, while the dogs will be kept under observation at suitable veterinary facilities within Local Health Authority 2. 

    Health authorities are monitoring the situation and adopting all necessary measures to protect human and animal health. 

    As a precaution, all dogs and cats in the Municipality of Vittorio Veneto must be vaccinated at a veterinary clinic.

    "The case has been monitored with the utmost care from the beginning, and within a couple of days, all possible contacts, both human and animal, were mapped," emphasized Director General Giancarlo Bizzarri. 

    "I therefore believe I can safely say that there is no cause for concern for the Vittorio Veneto population. Anyone with questions or requests for information can reach us via the telephone numbers provided by the ULSS."

    In light of the rabies case recorded in Vittorio Veneto and given that rabies is endemic in numerous non-European countries, ULSS 2 urges everyone to avoid interacting with animals when traveling to "at-risk" countries.

    This afternoon, the Municipality of Vittorio Veneto will publish an ordinance containing practical information for dog and cat owners. 


Contact point for veterinary questions : 336231711 | Contact point for medical questions : 3333360572

Source: 


Link: https://www.aulss2.veneto.it/Caso-di-rabbia-canina-a-Vittorio-Veneto-avviate-le-indagini-epidemiologiche-Tutti-i-cani-e-i-gatti-dovranno-essere-vaccinati

____

My New Space

Most Popular Posts